Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Bertrand

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Alzheimer Disease and Associated Disorders|August 20, 2013
Trends in recognition and treatment of dementia in france analysis of the 2004 to 2010 database of the national health insurance planMarion Bertrand, Christophe Tzourio, Annick Alpérovitch
Ophthalmology and Therapy|January 24, 2022
Risk of Myocardial Infarction, Stroke, or Death in New Users of Intravitreal Aflibercept Versus Ranibizumab: A Nationwide Cohort StudySophie Billioti de Gage, Marion Bertrand, Sébastien Grimaldi, et al.
Acta Ophthalmologica|June 14, 2021
Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational studySophie Billioti de Gage, Marion Bertrand, Sébastien Grimaldi, et al.
Journal of Epidemiology and Population Health|March 20, 2025
Utilisation des fluoroquinolones à usage systémique en France entre 2014 et 2023 : une étude à partir des données du Système National des Données de Santé (SNDS)Daniele Saade, Marie Joelle Jabagi, Marion Bertrand, et al.
NEJM Evidence|February 25, 2025
Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in InfantsMarie Joelle Jabagi, Jérémie Cohen, Marion Bertrand, et al.
Cerebrovascular Diseases (Basel, Switzerland)|January 3, 2007
Do extracellular-matrix-regulating enzymes play a role in cervical artery dissection?Benoît Guillon, Jacqueline Peynet, Marion Bertrand, et al.
Stroke|June 14, 2003
Infection and the risk of spontaneous cervical artery dissection: a case-control studyBenoît Guillon, Karine Berthet, Lamia Benslamia, et al.
JAMA|December 22, 2025
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in NewbornsMarie-Joelle Jabagi, Marion Bertrand, Amélie Gabet, et al.
Journal of the American Heart Association|November 2, 2016
Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient CareKim Bouillon, Marion Bertrand, Lotfi Boudali, et al.
The Lancet. Haematology|December 22, 2015
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort studyKim Bouillon, Marion Bertrand, Géric Maura, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Alzheimer Disease and Associated Disorders|August 20, 2013
Trends in recognition and treatment of dementia in france analysis of the 2004 to 2010 database of the national health insurance planMarion Bertrand, Christophe Tzourio, Annick Alpérovitch
Ophthalmology and Therapy|January 24, 2022
Risk of Myocardial Infarction, Stroke, or Death in New Users of Intravitreal Aflibercept Versus Ranibizumab: A Nationwide Cohort StudySophie Billioti de Gage, Marion Bertrand, Sébastien Grimaldi, et al.
Acta Ophthalmologica|June 14, 2021
Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational studySophie Billioti de Gage, Marion Bertrand, Sébastien Grimaldi, et al.
Journal of Epidemiology and Population Health|March 20, 2025
Utilisation des fluoroquinolones à usage systémique en France entre 2014 et 2023 : une étude à partir des données du Système National des Données de Santé (SNDS)Daniele Saade, Marie Joelle Jabagi, Marion Bertrand, et al.
NEJM Evidence|February 25, 2025
Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in InfantsMarie Joelle Jabagi, Jérémie Cohen, Marion Bertrand, et al.
Cerebrovascular Diseases (Basel, Switzerland)|January 3, 2007
Do extracellular-matrix-regulating enzymes play a role in cervical artery dissection?Benoît Guillon, Jacqueline Peynet, Marion Bertrand, et al.
Stroke|June 14, 2003
Infection and the risk of spontaneous cervical artery dissection: a case-control studyBenoît Guillon, Karine Berthet, Lamia Benslamia, et al.
JAMA|December 22, 2025
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in NewbornsMarie-Joelle Jabagi, Marion Bertrand, Amélie Gabet, et al.
Journal of the American Heart Association|November 2, 2016
Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient CareKim Bouillon, Marion Bertrand, Lotfi Boudali, et al.
The Lancet. Haematology|December 22, 2015
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort studyKim Bouillon, Marion Bertrand, Géric Maura, et al.
Pageof 5